MedTrace Logo

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

NCT04907149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-07-23

No results posted yet for this study

Summary

A study in healthy male volunteers to assess how the radiolabelled test medicine is taken up and broken down by the body when given by short infusion into a vein and when given by the mouth in the form of a tablet and an oral solution.

Conditions

  • Healthy

Interventions

DRUG

GLPG3970 film-coated tablet

Participants will receive a single oral dose of GLPG3970.

DRUG

[14C]GLPG3970 solution for infusion

Participants will receive an i.v. microtracer microdose.

DRUG

[14]GLPG3970 oral solution

Participants will receive a single oral dose \[14C\]GLPG3970.

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Ekaterina Tankisheva · Galapagos NV

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-07
Primary Completion
2021-07-12
Completion
2021-07-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04907149 on ClinicalTrials.gov